Arbutus Biopharma (ABUS) Tops Q2 EPS by 9c

Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.33), $0.09 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $1 million versus the consensus estimate of $590 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lands' End (LE) Tops Q1 EPS by 8c ; Offers Guidance
• RH (RH) Tops Q1 EPS by 12c